v3.26.1
CONCENTRATION
 6 Months Ended
Dec. 31, 2025
Risks and Uncertainties [Abstract]  
CONCENTRATION

NOTE 14 – CONCENTRATION

 

Business segments

 

The Company's operations are just organized into one business segment based on the nature of products and services offered. Summary operating results for each of its products were as follows:

 

   Three months Ended
December 31,		   Six months Ended
December 31,		 
   2025   2024   2025   2024 
Sales            
Anti-Aging & Immune Support  $26,805   $83,348   $170,754   $204,396 
Targeted System Support   14,252    7,591    45,630    26,669 
Herbal Insulin Support   4,043    -    16,275    - 
Total sales  $45,100   $90,939   $232,659   $231,065 
Cost of Goods Sold                    
Anti-Aging & Immune Support  $3,761   $7,199   $63,060   $16,647 
Targeted System Support   3,308    643    14,726    2,530 
Herbal Insulin Support   1,495    -    5,658    - 
Total cost of goods sold  $8,564   $7,842   $83,444   $19,177 
Gross Profit                    
Anti-Aging & Immune Support  $23,044   $76,149   $107,694   $187,749 
Targeted System Support   10,944    6,948    30,905    24,139 
Herbal Insulin Support   2,548    -    10,616    - 
Total operating profit  $36,536   $83,097   $149,215   $211,888 
Selling Expense                    
Anti-Aging & Immune Support  $12,127   $7,550   $16,971   $20,491 
Targeted System Support   6,237    906    12,139    2,703 
Herbal Insulin Support   13,150    -    23,216    - 
Total selling expense  $31,514   $8,456   $52,326   $23,194 

 

Major customers    

 

For the three months ended December 31, 2025, two major customers accounted for approximately 18% and 11% respectively of our total revenue in the period. For the three months ended December 31, 2024, only one major customer accounted for approximately 15% of our total revenue in the period. There was no concentration in accounts receivable for the three months ended December 31, 2025 and 2024.   

 

For the six months ended December 31, 2025, two major customers accounted for approximately 24% each of our total revenue in the period. For the six months ended December 31, 2024, only one customer accounted for approximately 14% of our total revenue in the period. There was no concentration in accounts receivable for the six months ended December 31, 2024. 

 

   For the three months ended December 31,   For the six months ended December 31, 
   2025   2024   2025   2024 
   Amounts   Percentages   Amounts   Percentages   Amounts   Percentages   Amounts   Percentages 
Customer A  $7,982    18%  $13,400    15%  $57,000    24%  $32,980    14%
Customer B  $4,824    11%  $-    -%  $55,877    24%  $-    -%

  

Major suppliers

 

For the three months ended December 31, 2025 and 2024, the Company had only one supplier representing 100% of the total purchases. There was no concentration in account payable for the three months ended December 31, 2025 and 2024.  

 

For the six months ended December 31, 2025, the Company had two suppliers representing approximately 57% and 39%, respectively of the total purchases. There was no concentration in account payable for the six months ended December 31, 2025. For the six months ended December 31, 2024, the Company had three suppliers representing approximately 68%, 19% and 13%, respectively of the total purchases. There was no concentration in account payable for the three months and the six months ended December 31, 2024.

 

   For the three months ended December 31,   For the six months ended December 31, 
   2025   2024   2025   2024 
   Amounts   Percentages   Amounts   Percentages   Amounts   Percentages   Amounts   Percentages 
Supplier A  $-    -   $-    -   $38,920    57%  $41,668    68%
Supplier B   4,760    100%   9,666    100%   26,457    39%   11,882    19%
Supplier C   -    -    -    -    2,673    4%   7,940    13%
   $4,760    100%  $9,666    100%  $68,050    100%  $61,490    100%